bit.bio

bit.bio is a pioneering cell programming company leveraging its proprietary opti-ox™ technology to deterministically convert induced pluripotent stem cells (iPSCs) into functional human cell types. This approach represents a paradigm shift from traditional, variable differentiation methods, offering unprecedented consistency and scalability. The company operates a dual business model, selling research-grade cells (ioCells) to the drug discovery market while building a therapeutic pipeline. With a recent $50 million Series C financing, bit.bio is positioned to scale its technology and advance its ambitious vision of creating accessible and affordable cell therapies.

opti-ox™ deterministic cell programming platform: a synthetic biology system that uses inducible transcription factor codes integrated into genomic safe harbour sites of iPSCs to synchronously and efficiently reprogram entire cell populations into any desired human cell type at scale.

In research tools, bit.bio competes with established iPSC differentiation companies like Fujifilm CDI. In therapeutics, it faces other iPSC engineering platforms (e.g., Century Therapeutics) and modality-specific cell therapy developers. Its key differentiator is the deterministic, synchronous nature of its opti-ox programming, promising superior consistency and scalability.